CN115666558A - 脂肪性肝病的治疗用药物 - Google Patents

脂肪性肝病的治疗用药物 Download PDF

Info

Publication number
CN115666558A
CN115666558A CN202180035760.4A CN202180035760A CN115666558A CN 115666558 A CN115666558 A CN 115666558A CN 202180035760 A CN202180035760 A CN 202180035760A CN 115666558 A CN115666558 A CN 115666558A
Authority
CN
China
Prior art keywords
formula
pharmaceutical composition
fatty liver
liver disease
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180035760.4A
Other languages
English (en)
Chinese (zh)
Inventor
雪冈日出男
岛崎淳行
滨田忠辉
大薮巨树
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shionogi and Co Ltd
Original Assignee
Shionogi and Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi and Co Ltd filed Critical Shionogi and Co Ltd
Publication of CN115666558A publication Critical patent/CN115666558A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
    • C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180035760.4A 2020-05-21 2021-05-20 脂肪性肝病的治疗用药物 Pending CN115666558A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020089196 2020-05-21
JP2020-089196 2020-05-21
JP2020134338 2020-08-07
JP2020-134338 2020-08-07
PCT/JP2021/019088 WO2021235508A1 (ja) 2020-05-21 2021-05-20 脂肪性肝疾患の治療用医薬

Publications (1)

Publication Number Publication Date
CN115666558A true CN115666558A (zh) 2023-01-31

Family

ID=78707930

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180035760.4A Pending CN115666558A (zh) 2020-05-21 2021-05-20 脂肪性肝病的治疗用药物

Country Status (10)

Country Link
US (2) US12521375B2 (https=)
EP (1) EP4154880A4 (https=)
JP (1) JP7820294B2 (https=)
KR (1) KR20230013126A (https=)
CN (1) CN115666558A (https=)
AU (1) AU2021275292A1 (https=)
CA (1) CA3182134A1 (https=)
MX (1) MX2022014553A (https=)
TW (1) TW202207919A (https=)
WO (1) WO2021235508A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4434520A4 (en) 2021-11-19 2025-10-29 Shionogi & Co PHARMACEUTICAL PRODUCT FOR THE TREATMENT OF HEART DISEASE OR SKELETAL MUSCLE DISEASE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009443A1 (en) * 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
US20160257641A1 (en) * 2013-10-17 2016-09-08 Shionogi & Co., Ltd. Novel alkylene derivatives
WO2017167934A1 (en) * 2016-03-30 2017-10-05 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
CN107428700A (zh) * 2015-03-30 2017-12-01 盐野义制药株式会社 9元稠环衍生物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523225A (ja) 2000-12-26 2004-08-05 リサーチ　ディベロップメント　ファンデーション 脂肪燃焼、脂肪蓄積、エネルギーホメオスタシス及びインシュリン作用の調節を標的とするアセチルコエンザイムａカルボキシラーゼ２
US6548738B2 (en) 2000-12-26 2003-04-15 Research Development Foundation ACC2-knockout mice and uses thereof
WO2011058474A1 (en) 2009-11-10 2011-05-19 Pfizer Inc. N1-pyrazolospiroketone acetyl-coa carboxylase inhibitors
BR112013010310A2 (pt) 2010-10-29 2016-11-29 Pfizer inibidores de acetil-coa carboxilase de lactama n1/n2
LT2776038T (lt) 2011-11-11 2018-04-25 Gilead Apollo, Llc Acc inhibitoriai ir jų panaudojimas
US20140187633A1 (en) 2012-12-31 2014-07-03 Amarin Pharmaceuticals Ireland Limited Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
JP6205152B2 (ja) 2013-03-25 2017-09-27 サイプレス セミコンダクター コーポレーション シリアル通信システム、受信装置およびシリアル通信方法
JP2018501276A (ja) 2015-01-09 2018-01-18 ギリアド アポロ， エルエルシー 非アルコール性脂肪肝疾患の処置のためのａｃｃ阻害剤併用療法
US11541046B2 (en) 2017-06-30 2023-01-03 Quixgen, Inc. Spirolactone compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110009443A1 (en) * 2008-05-28 2011-01-13 Kevin Daniel Freeman-Cook Pyrazolospiroketone Acetyl-Coa Carboxylase Inhibitors
US20160257641A1 (en) * 2013-10-17 2016-09-08 Shionogi & Co., Ltd. Novel alkylene derivatives
CN107428700A (zh) * 2015-03-30 2017-12-01 盐野义制药株式会社 9元稠环衍生物
WO2017167934A1 (en) * 2016-03-30 2017-10-05 Genfit Non-invasive diagnostic of non-alcoholic steatohepatitis
CN109072302A (zh) * 2016-03-30 2018-12-21 基恩菲特公司 非酒精性脂肪性肝炎的非侵入性诊断

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
朱韶杰: "ACC2抑制剂对NAFLD干预作用的实验研究", 《中国优秀硕士学位论文全文数据库》, no. 03, 15 March 2018 (2018-03-15), pages 13 *

Also Published As

Publication number Publication date
US20260091022A1 (en) 2026-04-02
JPWO2021235508A1 (https=) 2021-11-25
JP7820294B2 (ja) 2026-02-25
KR20230013126A (ko) 2023-01-26
CA3182134A1 (en) 2021-11-25
US12521375B2 (en) 2026-01-13
TW202207919A (zh) 2022-03-01
AU2021275292A1 (en) 2022-12-15
EP4154880A1 (en) 2023-03-29
EP4154880A4 (en) 2024-06-05
MX2022014553A (es) 2022-12-15
WO2021235508A1 (ja) 2021-11-25
US20230210822A1 (en) 2023-07-06

Similar Documents

Publication Publication Date Title
US20230065463A1 (en) Compounds and uses thereof
WO2021068380A1 (zh) 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
CN102844023A (zh) Cdc7激酶抑制剂以及其用途
JPWO2019013311A1 (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体
JP2011506563A (ja) ビスチアゾール誘導体、その製造方法および医薬品としてのその使用
CN107921035A (zh) 高苯丙氨酸血症及其治疗
US20200276196A1 (en) Substituted pyrimidine piperazine compound and use thereof
CN109071536A (zh) 具有ampk活化作用的5-苯基氮杂吲哚衍生物
US20260091022A1 (en) Pharmaceutical composition for treating fatty liver disease
JP2020111571A (ja) Ｍｇａｔ２阻害活性を有する縮合環誘導体を含有する医薬組成物
US20250263404A1 (en) Aminopyridines as activators of pi3 kinase
US20200216448A1 (en) Inhibitors of kidney-type glutaminase, gls-1
CA3102407A1 (en) Method of administering a therapeutically effective amount of 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
TW202128686A (zh) 稠合雜芳基類衍生物、其製備方法及其在醫藥上的應用
CN102665716A (zh) 用于治疗唐氏综合征的方法和药物组合物
US11730712B2 (en) Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease
US12274703B2 (en) Compositions and methods of treatment for neurological disorders comprising a dementia
US20250041279A1 (en) Therapeutic medicine for heart disease or skeletal muscle disease
US20240390333A1 (en) Neuroprotective compositions and methods of using the same
WO2021138450A1 (en) Novel small molecule shc blockers for treating liver disease and metabolic disease
US20250282783A1 (en) Protein stabilizing compounds containing usp28 and/or usp25 targeting ligands
HUE028725T2 (en) Diphenyl ether compounds for the treatment of liver and lung diseases, diabetes complications and cardiovascular diseases
US20050119197A1 (en) Naadp analogues for modulating t-cell activity
HK40082231A (en) Pharmaceutical for treating fatty liver diseases
CN109651395B (zh) 一种可靶向降解fkbp12及12.6的化合物及其制备方法和应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20230131